Department of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi
光学医療診療部・肝疾患センター
学術論文 2011
Wakita T, Suzuki T, Evans MJ, Shimotohno K, Chayama K, Matsuura Y, Hijikata M, et al. Will there be an HCV meeting in 2020? Summary of the 17th international meeting on hepatitis C virus and related viruses. Gastroenterology 2011;141:e1-5.
Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Kuzuya T, et al. Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology 2011;80:278-288.
Takaya D, Yamashita A, Kamijo K, Gomi J, Ito M, Maekawa S, Enomoto N, et al. A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors. Bioorg Med Chem 2011;19:6892-6905.
Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, Nakano M, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011;261:834-844.
Sakamoto M, Enomoto N. [Response to interferon therapy using mutations in the HCV-NS5A]. Nihon Rinsho 2011;69 Suppl 4:234-238.
Ohtaka M, Iwamoto F, Miura M, Matsui A, Shindo H, Yamaguchi T, Uetake T, et al. [A family with attenuated familial adenomatous polyposis identified because of fundic gland polyposis]. Nihon Shokakibyo Gakkai Zasshi 2011;108:945-953.
Motosugi U, Ichikawa T, Sano K, Sou H, Onohara K, Muhi A, Kitamura T, et al. Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol 2011;46:141-145.
Motosugi U, Ichikawa T, Sano K, Sou H, Onohara K, Muhi A, Amemiya F, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011;34:88-94.
Motosugi U, Ichikawa T, Oguri M, Sano K, Sou H, Muhi A, Matsuda M, et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 2011;29:1047-1052.
Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, et al. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. Antivir Ther 2011;16:685-694.
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011;54:439-448.
Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, et al. Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. Hepatol Int 2011;5:789-799.
Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, et al. Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. PLoS One 2011;6:e24514.
